Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Deferred Revenue
$1.68M
Quarterly · Period ending: · USD
LCTX Deferred Revenue
Latest reported$3.33Mperiod ending
Latest reported$3.33Mperiod ending
LCTX FY Deferred Revenue ($0.00 → $3.33M)
Annual deferred revenue
High-resolution chart · PNG
LCTX deferred revenue history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Deferred Revenue (USD) |
|---|---|
| 3,333,000 | |
| 7,388,000 | |
| 10,808,000 | |
| 9,421,000 | |
| 18,119,000 | |
| 193,000 | |
| 45,000 | |
| 42,000 | |
| 797,000 | |
| 572,000 | |
| 2,952,000 | |
| 208,357 | |
| 235,276 | |
| 400,870 | |
| 465,544 | |
| 550,083 | |
| 367,904 | |
| 312,904 | |
| 261,091 | |
| 183,935 | |
| 140,000 | |
| 901,563 | |
| 407,813 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |